Donepezil: Clinical Trials

70 trials of Donepezil, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

40 completed, 11 terminated, 11 unknown, 3 recruiting. 70 Phase 2, 3 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 270Completed 40, Terminated 11, Unknown 11, Recruiting 3, Not yet recruiting 2, Withdrawn 2, Active not recruiting 1
Phase 13Active not recruiting 1, Completed 1, Withdrawn 1
Phase 33Unknown 2, Recruiting 1

Follow Donepezil: new trials by email Literature Review of Donepezil trials Research Report on Donepezil

Trials (filtered) newest first · largest first

All 70 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa
Donepezil - Anorexia Nervosa
Phase 2Not yet recruitingNew York State Psychiatric Institute102027-01-012026-10-23
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Huperzine A Controlled-Release Tablets, Donepezil hydrochloride tablets, Huperzine A controlled-release tablets placebo; Donepezil hydrochloride tablets placebo - Alzheimer Dementia
Phase 2 / Phase 3RecruitingWanbangde Pharmaceutical Group Co., LTD7202025-08-292026-08-17
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
Donepezil, Memantine - Osteoporosis
Phase 2RecruitingDuke University452025-02-032026-09-21
Acetylcholinesterase Inhibitor in Anorexia Nervosa: Multicenter, Double-Blind, Placebo-Controlled Trial
Donepezil 2.5 mg, Donepezil 5 mg, Placebo Comparator - Anorexia Nervosa Restricting Type
Phase 2Not yet recruitingCentre Hospitalier St Anne1472024-11-012024-11-14
Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease
Donepezil (Aricept) - Parkinson Disease
Phase 2CompletedUniversity of Virginia62024-11-012026-03-09
Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease
Donepezil Hydrochloride, Placebo - Parkinson Disease, Mild Cognitive Impairment
Phase 2UnknownFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau1202023-10-012023-09-28
A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.
Aricept Tablet, IVL3003 - Alzheimer Disease
Phase 1 / Phase 2Active not recruitingInventage Lab., Inc.622023-04-012024-12-19
Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)
Donepezil + Cognitive remediation therapy (CRT), Donepezil + Placebo CRT, Placebo medication + Cognitive remediation therapy (CRT) - Alcohol Use Disorder
Phase 2RecruitingVA Connecticut Healthcare System1602022-08-082026-06-23
Donepezil for Oxaliplatin-induced Neuropathy Peripheral Neuropathy: Proof of Concept Study
DONEPEZIL, PLACEBO - Digestive Oncology, Supportive Care
Phase 2CompletedUniversity Hospital, Clermont-Ferrand772022-06-022024-04-05
Efficacy of Chinese Traditional Medicine "Smart Soup" in Cognition and Behavior Regulation in Alzheimer's Disease
smart soup, Donepezil, Memantine - Alzheimer Disease, Mild Cognitive Impairment
Phase 2UnknownPeking Union Medical College Hospital1802022-06-012022-09-14
A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease
PM012, PM012 Placebo, Donepezil - Mild Alzheimer Disease
Phase 2 / Phase 3UnknownMediforum Ltd., Co.3122020-11-272023-04-18
The Effect of Donepezil on Wound Healing
Donepezil, Placebo oral tablet, Topical Zinc Oxide - Wound Heal
Phase 2UnknownUniversity of Maryland, Baltimore202020-08-302023-05-22
The Effect of Donepezil on Glycemic Control in Type II Diabetics
Donepezil 5-10 Mg Oral Tablet, Placebo Oral Tablet - Diabetes Mellitus, Type 2
Phase 2TerminatedUniversity of Maryland, Baltimore72019-07-122023-10-13
The Effect of Donepezil in Radiotherapy-related Cognitive Impairment.
Donepezil Hydrochloride, Placebo - Radiation Injuries, Cognitive Impairment
Phase 2UnknownSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2382019-05-012019-11-25
Effect of Electroacupuncture Combined With Donepezil for Treating Alzheimer's Disease
acupuncture, donepezil - Cognitive Impairment
Phase 2UnknownGuang'anmen Hospital of China Academy of Chinese Medical Sciences3342017-06-012017-05-16
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)
Donepezil, DHP1401, Placebo - Mild-moderate Alzheimer's Disease
Phase 2CompletedDaehwa Pharmaceutical Co., Ltd.1802016-12-282019-08-20
A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients
Duloxetine, Donepezil, Modafinil - Parkinson's Disease
Phase 2WithdrawnUniversity of Chicago2016-11-012017-12-12
Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease
Ginkgo biloba dispersible tablets, Donepezil, Ginkgo biloba dispersible tablets and Donepezil - Alzheimer's
Phase 2 / Phase 3UnknownThe First Affiliated Hospital with Nanjing Medical University2402016-08-102019-08-07
Study of STA-1 as an Add-on Treatment to Donepezil
Donepezil,, STA-1, placebo - Alzheimer Disease
Phase 2UnknownSinphar Pharmaceutical Co., Ltd1362015-12-012014-08-20
A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
Donepezil, Solifenacin - Dementia of Alzheimer's Type
Phase 2CompletedChase Pharmaceuticals Corporation, an affiliate of Allergan plc282015-10-072019-03-05

Showing 20 of 70. Sign in to see all of them.

Conditions studied

Alzheimer Disease (31)  ·  Cognitive Dysfunction (7)  ·  Dementia (7)  ·  Parkinson Disease (6)  ·  Autism Spectrum Disorder (3)  ·  Autistic Disorder (3)  ·  Cognition Disorders (3)  ·  Anorexia Nervosa (2)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Delirium (2)  ·  Down Syndrome (2)  ·  Feeding and Eating Disorders (2)  ·  Habits (2)  ·  Lewy Body Disease (2)

Sponsors

AbbVie (prior sponsor, Abbott) (4)  ·  Eisai Inc. (4)  ·  GlaxoSmithKline (3)  ·  AstraZeneca (2)  ·  Eisai Co., Ltd. (2)  ·  Eisai Limited (2)  ·  National Center for Research Resources (NCRR) (2)  ·  National Institute of Mental Health (NIMH) (2)  ·  Sanofi (2)  ·  University of Maryland, Baltimore (2)  ·  Wake Forest University Health Sciences (2)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Birte Glenthoj (1)  ·  Boehringer Ingelheim (1)

Countries

United States (37)  ·  United Kingdom (9)  ·  Russia (8)  ·  Germany (7)  ·  South Korea (7)  ·  Australia (6)  ·  Canada (6)  ·  Czechia (6)  ·  France (6)  ·  Poland (6)  ·  South Africa (6)  ·  Spain (6)  ·  China (5)  ·  Ukraine (5)  ·  Bulgaria (4)

Top investigators

Itaru Arimoto (2)  ·  Laura Gault, MD (2)  ·  Allan L Reiss (1)  ·  Andrew Strasser, MBBS, PhD (1)  ·  Ashura W Buckley, M.D. (1)  ·  Benjamin L. Handen, PhD (1)  ·  Bertrand Gaymard, MD, PhD (1)  ·  Birte Glenthoj, MD, DMSc. (1)

Results publications

PMID 29854923, PMID 16549835, PMID 18296124, PMID 19836169, PMID 20872778, PMID 21295494, PMID 21679156, PMID 22091574, PMID 24418055, PMID 26697847, PMID 27662321, PMID 27756421, PMID 28550255, PMID 28673322, PMID 29854928, PMID 30755255, PMID 33189083, PMID 35662833, PMID 35799138, PMID 35908254, PMID 36168659, PMID 37267443, PMID 39111388, PMID 39566720

NIH funding

2009 (3), U10CA081851 (2), 2004 (1), R01AA029075 (1), R21AG027549 (1), R21AG078982 (1), R21DA029787 (1), R21MH064941 (1), R34MH085899 (1), R56AG021476 (1)